TIGIT Promotes Tumor Immune Escape via CD8 + T-cell Exhaustion

2014 Cancer Discovery  
JANUARY 2015 CANCER DISCOVERY | 11 Major finding: Co-inhibition of TIGIT and PDL1 promotes CD8 + T-cell effector function and prevents tumor growth. Mechanism: TIGIT drives CD8 + T-cell dysfunction by disrupting CD226 homodimerization in cis. Impact: TIGIT may represent a useful immunotherapy target in cancer and chronic viral infections.
doi:10.1158/2159-8290.cd-rw2014-253 fatcat:4b7u5uwpejdubg7nnctacq2blu